How Do Allergy Drops Work? The Immunology of SLIT

The under-the-tongue location is chosen because the oral mucosa there is unusually tolerogenic, meaning it is biased toward calming the immune system rather than triggering inflammation. The tissue is rich in specialized antigen-presenting cells, including Langerhans cells, that capture the allergen and deliver a tolerance-promoting message to the immune system. If the allergen were simply swallowed without that contact time, it would largely bypass this tissue and pass into the digestive tract, missing the cells that drive desensitization. Holding the drops in place for about two minutes gives these oral immune cells time to sample the allergen. This is why the sublingual route is central to how the treatment works, not just a convenience.

IgG4 is a type of antibody often called a blocking antibody. In allergic disease, the troublemaker antibody is IgE, which sits on mast cells and basophils and triggers histamine release when it grabs an allergen. As sublingual immunotherapy progresses, the immune system increases production of allergen-specific IgG4. This IgG4 binds the allergen first and competes with IgE, so fewer allergen molecules reach the IgE on those cells. The result is less crosslinking of IgE and a weaker allergic reaction. Rising IgG4 is considered one of the measurable signatures that immunotherapy is engaging the immune system, although antibody levels alone do not perfectly predict how a given person will feel.

The underlying immune changes begin early but build slowly. Shifts in regulatory T cell activity and antibody production can start within the first weeks to months of consistent dosing, and some people notice symptom improvement during the first allergy season on treatment. However, the deeper, more durable reprogramming of the immune system that can outlast treatment takes far longer, which is why a course of roughly three to five years is generally recommended. Stopping early, before tolerance is consolidated, makes it more likely that benefits fade. Daily consistency is important because the immune system needs steady, repeated exposure to keep moving toward tolerance rather than drifting back.

Allergy drops are disease-modifying, meaning they can genuinely change the immune response rather than just masking symptoms, but that is not the same as a cure. The treatment shifts the immune system toward tolerance and can reduce sensitivity for many people, sometimes with benefits that persist after treatment ends. Still, the degree of improvement varies, allergies are not eliminated for everyone, and there is no guarantee of a permanent result. It is more accurate to say drops may provide long-term relief and address the underlying allergic response than to call them a cure. The honest framing the evidence supports is meaningful, often lasting improvement, not a guaranteed elimination of allergy.

Immunotherapy does measurably alter the antibody picture over time, though the relationship to how you feel is imperfect. As treatment progresses, allergen-specific IgG4 blocking antibodies rise substantially, and after sustained treatment some studies show allergen-specific IgE begins to fall as well, often after an initial transient bump early in the course. These shifts are part of how researchers confirm that immunotherapy is engaging the immune system. However, antibody levels are not a reliable scorecard for an individual: someone can have favorable lab changes yet only modest symptom relief, or vice versa. For that reason, clinicians generally judge success by how your symptoms and medication needs change, not by repeating blood tests, which are mainly used for the initial diagnosis.